About MRD

Keeping an eye on your cancer is an essential part of treating it

What is MRD?

Measurable (or minimal) residual disease (MRD) refers to the small number of cancer cells that may remain in the body during and after treatment.1

Even if you are responding well to treatment or are in remission, MRD can be present at such low levels that it doesn’t cause any physical signs or symptoms, which may be a sign that your cancer is returning.1

When it comes to treating blood cancer, your doctor’s ability to detect these traces of disease may be important for making timely and informed decisions about your treatment plan.1-5

clonoSEQ is a test that helps your doctor keep an eye on your MRD throughout your cancer journey

Measuring MRD with clonoSEQ

Multiple myeloma is an ever-changing disease.

MRD testing can help you and your doctor:

  • Understand your cancer and make a treatment plan1
  • Assess how the amount of cancer in your body is changing over time2
  • Uncover information other tests
    may miss2,3,6-8
  • Measure your response to treatment, and potentially adjust your treatment plan to improve the outcome4
  • Detect the return of cancer before physical signs and symptoms arise2,9-14

The insights you and your doctor get from clonoSEQ MRD testing can support shared decision-making throughout the course of your care

In a survey of multiple myeloma patients who reported having MRD testing15:

99%

found it useful

81%

said it gave them more confidence

73%

said it helped them make treatment decisions

Talk to your doctor about clonoSEQ

Here are some questions to help you start a conversation with your doctor.

  • What is MRD?
  • How will measuring MRD inform decisions related to my cancer treatment?
  • At what points during my treatment plan might I need MRD testing?
  • What might a positive or negative MRD result mean for me?

Together, you and your healthcare team can track your MRD results and use them to inform important treatment decisions.

Learn about clonoSEQ

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

References:

  1. clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020.
  2. Pulsipher M, et al. Blood. 2015;125(22):3501-3508.
  3. Wood B, et al. Blood. 2018;131(12):1350-1359.
  4. Perrot A, et al. Blood. 2018;132(23):2456-2464.
  5. Thompson P, et al. Blood. 2019;134(22):1951-1959.
  6. Short N, et al. Blood Adv. 2022;6(13):4006-4014.
  7. Pulsipher M, et al. Blood Cancer Discov. 2022;3(1):66-81.
  8. Avet-Loiseau H, et al. Blood. 2015;126(23):191.
  1. Logan A, et al. Biol Blood Marrow Transplant. 2014;20(9):1307-1313.
  2. Roschewski M, et al. Lancet Oncol. 2015;16(5):541-549.
  3. Rezazadeh A, et al. Clin Lymphoma Myeloma Leuk. 2023;2152-2650.
  4. Al-Sawaf O, et al. J Clin Oncol. 2021;39(36):4049-4060.
  5. Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.
  6. Costa L, et al. Lancet Haematol. 2023;10(11):e890-e901.
  7. Hydren J, et al. Paper presented at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Abstract 2410.